New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Larimar Therapeutics, Inc.
LRMR
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

509M

Biotechnology

Next Earning date - 12 Nov 2024

509M

Biotechnology

Next Earning date - 12 Nov 2024

7.98USD
Shape-0.03 ( -0.37%)
Market Open
favorite-chart

Relative Strenght

92
favorite-chart

Volume Buzz

-44%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

42%

Quote Panel

Shape
Updated October 28, 2024
1W 6.24 % 1M 22.14 % 3M -10.91 % 1Y 173.97 %

Key Metrics

Shape
  • Market Cap

    509.18M


  • Shares Outstanding

    63.81M


  • Share in Float

    37.27M


  • Dividende

    0


  • Earning Date

    12 Nov 2024


  • Price Target

    7.98


  • Average Volume

    575570


  • Beta

    0.762


  • Range

    2.18-13.68


  • Industry

    Biotechnology


  • Website

    https://www.larimartx.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

0.00x

P/S Ratio

2.42x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$-1.1

EPS

How LRMR compares to sector?

P/E Ratio

Relative Strength

Shape

LRMR

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape
0

$1.90

Shape-459%

2025-EPS

0

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Oppenheimer

initialise

Previous: Not converted

2024-10-15

Now: Outperform

Wedbush

initialise

Previous: Not converted

2024-10-03

Now: Outperform

H.C. Wainwright

initialise

Previous: Not converted

2024-10-02

Now: Buy

Citigroup

initialise

Previous: Not converted

2022-12-13

Now: Neutral

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.37
vs -0.92

Q4.22

arrow
arrow

N/A

-0.21
vs -0.50

Q1.23

arrow
arrow

N/A

NA
vs -0.49

Q2.23

arrow
arrow

N/A

-0.19
vs -0.47

Q3.23

arrow
arrow

N/A

-0.21
vs -0.37

Q4.23

arrow
arrow

N/A

-0.30
vs -0.21

Q1.24

arrow
arrow

N/A

-0.27
vs NA

Q2.24

arrow
arrow

N/A

-0.34
vs -0.19

Q3.24

arrow
arrow

N/A

-0.37
vs -0.21

Q4.24

arrow
arrow

N/A

-0.40
vs -0.30

Sales GrowthShape

status-upYoY

Current

Estimates

Q1.22

arrow
arrow

NA

NA  vs NA

Q2.22

arrow
arrow

NA

NA  vs NA

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

NA  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-7%

-0.07
vs -0.17

Q4.22

arrow
arrow

-8%

-0.08
vs -0.07

Q1.23

arrow
arrow

-5%

-0.05
vs -0.08

Q2.23

arrow
arrow

-8%

-0.08
vs -0.05

Q3.23

arrow
arrow

-10%

-0.10
vs -0.08

Q4.23

arrow
arrow

-16%

-0.16
vs -0.10

Q1.24

arrow
arrow

-6%

-0.06
vs -0.16

Q2.24

arrow
arrow

-10%

-0.10
vs -0.06

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

53

53
vs 36

47%

Q4.22

arrow
arrow

48

48
vs 53

-9%

Q1.23

arrow
arrow

69

69
vs 48

44%

Q2.23

arrow
arrow

67

67
vs 69

-3%

Q3.23

arrow
arrow

67

67
vs 67

NA

Q4.23

arrow
arrow

74

74
vs 67

10%

Q1.24

arrow
arrow

112

112
vs 74

51%

Q2.24

arrow
arrow

110

110
vs 112

-2%

Earnings Growth

Latest News